BC Partners Said to Consider Sale of Diagnostics Firm Synlab

Buyout firm BC Partners is exploring the sale of German laboratory operator Synlab amid a boom in health-care deals, people with knowledge of the matter said.

BC Partners is working with Rothschild on the potential sale, which is set to kick off this year, the people said, asking not to be identified because deliberations are private.

Synlab may attract interest from strategic companies including Fresenius Medical Care AG as well as private-equity firms, they said. No final decision has been made and BC Partners may decided against the disposal, they said.

Buying a clinical laboratory and diagnostics services company would allow Fresenius Medical to add to the dialysis and patient care centers it already operates, giving the company a role in the whole medical system from diagnosis through to treatment and care.

Representatives for London-based BC Partners, Rothschild and Fresenius Medical declined to comment.

BC Partners invested in Synlab in 2009 in a transaction valued at 618 million euros ($683 million), according to the buyout firm’s website. Synlab, based in Augsburg, Germany, also runs labs in 22 other European countries as well as Turkey, Saudi Arabia and the United Arab Emirates.

Before it's here, it's on the Bloomberg Terminal.